RxDoctor Payments Data

Charlsie Taylor, PA

Medical · Gainesville, GANPI 1962948422

Payments from drug & device makers

$5,373in general payments, 2019–2025

Across 209 payments — averaging $25.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Sanofi$2K
  • Amgen$1K
  • UCB, Inc.$129
  • Novartis$127
  • Johnson & Johnson$69
  • plus $84 from 2 others

What the payments were for

  • Food & beverage$5,31899%
  • Education$551%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie94$2,080
Sanofi18$1,815
Amgen77$1,069
UCB, Inc.6$129
Novartis8$127
Johnson & Johnson2$69
GSK3$62
Organon1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,373 in reported general payments places this provider in the 85th percentile of 950 medical providers in Georgia.

See all medical providers in Georgia

Medicare billing

Part B allowed, 2024
$77,083
Medicare patients
236
Services billed
3,959

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab96$1,093,700
Enbrel SureclickEtanercept64$505,015
RinvoqUpadacitinib55$471,944
Skyrizi PenRisankizumab-Rzaa13$330,457
Cosentyx Sensoready (2 Pens)Secukinumab30$225,292
Humira PenAdalimumab17$127,568
Actemra ActpenTocilizumab23$106,302
OtezlaApremilast17$98,207
BenlystaBelimumab11$52,202
KevzaraSarilumab12$51,053
Hydroxychloroquine Sulfate415$21,426
MethotrexateMethotrexate Sodium326$8,726
Febuxostat53$6,543
Mycophenolate Mofetil31$3,977
Colchicine59$3,345

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$2,080$471,94455 claims
AmgenOtezla$1,069$98,20717 claims
GSKBenlysta$62$52,20211 claims
SanofiKevzara$1,815$51,05312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 950 medical providers in Georgia.

Other medical in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →